A PHASE I DOSE-ESCALATION STUDY OF XL765 IN COMBINATION WITH TEMOZOLOMIDE WITH AND WITHOUT RADIATION IN SUBJECTS WITH MALIGNANT GLIOMAS.

Trial Profile

A PHASE I DOSE-ESCALATION STUDY OF XL765 IN COMBINATION WITH TEMOZOLOMIDE WITH AND WITHOUT RADIATION IN SUBJECTS WITH MALIGNANT GLIOMAS.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Sep 2015

At a glance

  • Drugs Temozolomide (Primary) ; Voxtalisib (Primary)
  • Indications Anaplastic astrocytoma; Glioblastoma; Glioma; Oligodendroglioma
  • Focus Adverse reactions
  • Sponsors Exelixis; Sanofi
  • Most Recent Events

    • 01 Feb 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 30 Jan 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 27 Sep 2012 Planned End Date changed from 1 Aug 2012 to 1 Feb 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top